Research programme: antibody biosimilars - Prestige Biopharma

Drug Profile

Research programme: antibody biosimilars - Prestige Biopharma

Alternative Names: Bevacizumab biosimilar - Prestige BioPharma/Hanwha Biologics; HD 204; HD 205

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanwha Biologics
  • Developer Hanwha Biologics; Prestige BioPharma
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued Autoimmune disorders

Most Recent Events

  • 08 Aug 2017 Discontinued for Autoimmune disorders in South Korea (Parenteral)
  • 18 Jan 2017 Preclinical trials in Solid tumours in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top